The FDA warned Eli Lilly and Co. for giving consumers misleading information about its cancer drug Alimta.
In a brochure for patients, the drug maker failed to say which specific conditions Alimta treats, according to the FDA's letter of July 27, 2006 and released on its Web site.
The brochure informs patients that "Alimta is a chemotherapy drug used to treat certain types of cancer." d.
Alimta is approved to treat non-small cell lung cancer or in some cases mesothelioma. According to the warning letter, the brochure also fails to tell patients that there were no trials showing a clinical benefit such as improved survival or relief of symptoms in patients with non-small cell lung cancer.
Go here for more.